References: Wojtowicz-Praga,S.M.; Dickson,R.B.; Hawkins,M.J.. Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15:61-75. (Link)
Hornebeck,W.. Down-regulation of tissue inhibitor of matrix metalloprotease-1 (TIMP-1) in aged human skin contributes to matrix degradation and impaired cell growth and survival. Pathol.Biol.(Paris) 2003;51:569-573. (Link)
Yan,L.; Moses,M.A.. A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma. Am.J.Pathol. 2001;158:1185-1190. (Link)
Shin,W.S.; Szuba,A.; Rockson,S.G.. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 2002;160:91-102. (Link)
Nagase,H.; Meng,Q.; Malinovskii,V.; Huang,W.; Chung,L.; Bode,W.; Maskos,K.; Brew,K.. Engineering of selective TIMPs. Ann.N.Y.Acad.Sci. 1999;878:1-11. (Link)
Thorgeirsson,U.P.; Lindsay,C.K.; Cottam,D.W.; Gomez,D.E.. Tumor invasion, proteolysis, and angiogenesis. J.Neurooncol. 1994;18:89-103. (Link)
Gardner,J.; Ghorpade,A.. Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system. J.Neurosci.Res. 2003;74:801-806. (Link)
Arthur,M.J.; Iredale,J.P.. Hepatic lipocytes, TIMP-1 and liver fibrosis. J.R.Coll.Physicians Lond 1994;28:200-208. (Link)
Nagase,H.; Brew,K.. Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors. Biochem.Soc.Symp. 2003;201-212. (Link)